FindMyKOL

David Planchard, MD

Enriched profile

Thoracic oncologist, Gustave Roussy; Associate Professor, Université Paris-Saclay · Gustave Roussy

ORCID↗RPPS

Licensed physician in France · practises at Institut Gustave Roussy Site Ville Juif · RPPS register, 2026-10-19

✓ Itemized profile
Region🇫🇷 FranceSpecialtyPneumologieFocusLung Cancer Treatments and Mutations+4
Active KOLFindMyKOL type: EliteLatest publication2026Online presenceNone verifiedPaymentsNot attributedNIH fundingNone on fileWhy? →

David Planchard is Thoracic oncologist, Gustave Roussy; Associate Professor, Université Paris-Saclay at Gustave Roussy. OpenAlex indexes 749 publications with 52,197 citations (h-index 88); ClinicalTrials.gov lists 9 registered studies with this person as an investigator.

Data verified 8 Nov 2026

Overview

Updated 8 Nov 2026

David Planchard is Thoracic oncologist, Gustave Roussy. The public record shows 749 publications with 52,197 citations (h-index 88), centered on Lung Cancer Treatments and Mutations, Lung Cancer Diagnosis and Treatment, Cancer Immunotherapy and Biomarkers. It also documents an investigator role on 9 registered clinical trials.

  • Most recent indexed publication: 2026 · Clinical cancer research
  • Top research focus: Lung Cancer Treatments and Mutations
  • 9 registered trials on ClinicalTrials.gov

Generated from the cited public record · current as of 8 Nov 2026. Every fact links its source below.

Indications focus

from trials led + research topics
Lung Cancer (NSCLC/SCLC)8 trialsSmall Cell Lung Carcinoma8 trialsMelanoma1 trialNeoplasm Metastasis1 trialBrain Neoplasms1 trialIBD (Crohn's / UC)Ovarian / Gynecologic CancerMultiple SclerosisGastroesophageal CancerPancreatic CancerLupus (SLE)Breast CancerHead & Neck CancerTuberculosisColorectal CancerMyasthenia GravisIBS / Functional GIBladder / Urothelial CancerLeukemia (AML/ALL/CML/CLL)HIVIdiopathic Pulmonary FibrosisNeuro-Oncology / GliomaHepatobiliary CancerAcromegaly

Research focus

OpenAlex concept fingerprint
Lung Cancer Treatments and MutationsLung Cancer Diagnosis and TreatmentCancer Immunotherapy and BiomarkersLung Cancer Research StudiesCancer Genomics and Diagnostics

Drugs & molecules

across trials, industry payments and publications
3-(3-Chloro-2-methoxyanilino)-7-(2-methoxyethyl)-2-(2-methylpyrimidin-4-yl)-1,5-dihydropyrrolo[3,2-c]pyridin-4-oneClinical trials1Industry payments—Publications—

Works with

trial sponsors and companies reporting payments
Gustave Roussy, Cancer Campus, Grand ParisClinical trials2Industry payments—Intergroupe Francophone de Cancerologie ThoraciqueClinical trials2Industry payments—Pierre Fabre MedicamentClinical trials2Industry payments—UnicancerClinical trials2Industry payments—AstraZenecaClinical trials1Industry payments—

Scholarship

indexed output and impact (OpenAlex)
View publications ↓
749publications

Publications indexed by OpenAlex, matched via ORCID. 19 in PubMed. Counts exclude supporting files.

52,197citations

Citations across these publications.

88h-index

H-index from these publications. i10-index 288.

Clinical & industry

trials, payments and federal funding
9clinical trials

Investigator role on registered studies.

View trials ↓
—payment companies

Not shown. No U.S. clinical registration on file.

0NIH grants

Federally funded research awards.

This is a research profile, built on the published record. There's no U.S. clinical registration (NPI) on file, so facts that hang off one (clinical specialty, industry payments) aren't shown. We'd rather leave a gap than guess. Why? →

Contact

No public contact details on file. Research profiles have no U.S. clinical registration, so there's no federal registry record to draw an address or phone from. Why? →

Clinical trials

Updated 8 Nov 2026

Listed as an investigator on 9 registered studies on ClinicalTrials.gov. The most recent:

All 9 trial records: search, sort and filter.Explore →

Industry payments

Not shown. This person has no U.S. clinical registration (NPI) on file, so we can't reliably tie industry payments reported to CMS to them. We'd rather leave a gap than guess. Why? →

NIH funding

We didn't find any NIH-funded research awards for this person in NIH RePORTER. Why? →

Congress activity

Updated 8 Nov 2026

240 congress contributions (2004–2026) across AACR, ASCO, ASTRO, ESMO, IASLC, ISPOR Europe per OpenAlex. The most recent:

All 240 congress records: search, sort and filter.Explore →

Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.

Publications

Updated 8 Nov 2026

Their five most recent publications, matched to their ORCID record and linked to PubMed.

All 19 publications: search, sort and filter.Explore →

Background & recognition

Updated 8 Nov 2026

Credentials, appointments and honors, newest first, each linked to the public source it came from.

Education

degrees and training on record
  • MD

    PhD

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →onclive.com ↗

Editorial & leadership roles

journal and society appointments

Awards & honors

honors on the public record

Secondary affiliations

appointments beyond the home institution
  • PMNCO research unit

    Univ. Paris-Saclay / French National Institute of Health and Medical Research (Inserm) / Gustave Roussy

    verifiedCorroborated by FindMyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →universite-paris-saclay.fr ↗

Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.

Similar KOLs

Other experts from the same institution or the same specialty.